Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. / Sørensen, Rikke Bæk; Køllgaard, Tania; Andersen, Rikke Sick; van den Berg, Joost Huibert; Svane, Inge Marie; Straten, Per thor; Andersen, Mads Hald.
I: Cancer Research, Bind 71, Nr. 6, 15.03.2011, s. 2038-44.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2
AU - Sørensen, Rikke Bæk
AU - Køllgaard, Tania
AU - Andersen, Rikke Sick
AU - van den Berg, Joost Huibert
AU - Svane, Inge Marie
AU - Straten, Per thor
AU - Andersen, Mads Hald
N1 - ©2011 AACR
PY - 2011/3/15
Y1 - 2011/3/15
N2 - Several lines of data have suggested a possible link between the indoleamine 2,3-dioxygenase (IDO)-like protein IDO2 and cancer. First, IDO2 expression has been described in human tumors, including renal, gastric, colon, and pancreatic tumors. Second, the apparent selective inhibition of IDO2 by the D stereoisomer of the IDO blocker 1-methyl-tryptophan (1MT), which tends to be more active than the L-isomer in a variety of biological assays for IDO function, suggests that IDO2 may be important to sustain immune escape and growth of tumors. Especially, D-1MT heightens chemotherapeutic efficacy in mouse models of cancer in a nontoxic fashion. Here, we describe the immunogenicity of IDO2 by showing the presence of spontaneous cytotoxic T-cell reactivity against IDO2 in peripheral blood of both healthy donors and cancer patients. Furthermore, we show that these IDO2-specific T cells are cytotoxic effector cells that recognize and kill tumor cells. Our data suggest that IDO2 might be a useful target for anticancer immunotherapeutic strategies.
AB - Several lines of data have suggested a possible link between the indoleamine 2,3-dioxygenase (IDO)-like protein IDO2 and cancer. First, IDO2 expression has been described in human tumors, including renal, gastric, colon, and pancreatic tumors. Second, the apparent selective inhibition of IDO2 by the D stereoisomer of the IDO blocker 1-methyl-tryptophan (1MT), which tends to be more active than the L-isomer in a variety of biological assays for IDO function, suggests that IDO2 may be important to sustain immune escape and growth of tumors. Especially, D-1MT heightens chemotherapeutic efficacy in mouse models of cancer in a nontoxic fashion. Here, we describe the immunogenicity of IDO2 by showing the presence of spontaneous cytotoxic T-cell reactivity against IDO2 in peripheral blood of both healthy donors and cancer patients. Furthermore, we show that these IDO2-specific T cells are cytotoxic effector cells that recognize and kill tumor cells. Our data suggest that IDO2 might be a useful target for anticancer immunotherapeutic strategies.
U2 - http://dx.doi.org/10.1158/0008-5472.CAN-10-3403
DO - http://dx.doi.org/10.1158/0008-5472.CAN-10-3403
M3 - Journal article
VL - 71
SP - 2038
EP - 2044
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 6
ER -
ID: 40197095